The IT major will make use of the Veeva Development Cloud platform to support Boehringer Ingelheim to unify medicinal development processes and data into a connected technology ecosystem
Cognizant partners with Boehringer Ingelheim to advance speed and quality of medicinal therapy development. (Credit: Nur Cholis/Wikimedia Commons)
Cognizant has announced a partnership with biopharmaceutical company Boehringer Ingelheim to advance the speed and quality of medicinal therapy development with an integrated cloud platform.
In this connection, Cognizant will make use of the Veeva Development Cloud platform to support Boehringer Ingelheim to bring together medicinal development processes and data into a connected technology ecosystem.
This is expected to improve partnerships across clinical, regulatory, and quality functions.
According to Cognizant, Boehringer Ingelheim’s connected ecosystem, labelled as the ‘One Medicine Platform’ will become one of the largest global implementations of Veeva technology.
The holistic strategy of integrating Boehringer Ingelheim’s clinical, regulatory, and quality functions onto the unified platform simultaneously is anticipated to boost operational efficiency and interoperability.
Boehringer Ingelheim global clinical development senior vice president Uli Brӧdl said: “Achieving an end-to-end platform to help speed the development of life-changing therapies has been an elusive goal for many organisations, and we’re making that vision a reality.
“Our collaborations with Cognizant and Veeva are empowering us to advance this important programme that will positively impact patient lives.”
The Boehringer Ingelheim engagement was started by Cognizant with an examination of the biopharma manufacturer’s business and technology. This was followed by the development of the programme plan and the agile methodology for system integration.
In partnership with Veeva, Cognizant is now delivering services, including system architecture and design, programme management, data migration, training, integration, testing and validation services.
Cognizant life sciences global head Srini Shankar said: “Utilising advanced technologies to improve the quality and delivery of novel medicines is a must for innovative pharmaceutical companies, and Boehringer Ingelheim stands out for their forward thinking in pursuing development of the One Medicine Platform.
“Veeva has been recognised as one of the fastest growing life sciences technology companies, and Cognizant is a skilled system integrator with the expertise necessary to simultaneously implement multiple Veeva platforms.”
Last week, Cognizant extended its healthcare partnership with Microsoft to bring the latter’s cloud-based technology solutions to the healthcare market.